Martin H. Voss, MD, on Bringing Different Disciplines Together at IKCS

Article

The medical oncologist discusses the different talks that were presented at the International Kidney Cancer Symposium in Miami.

Martin H. Voss, MD, from Memorial Sloan Kettering Cancer Center, discussed the various talks being presented at the International Kidney Cancer Symposium, held November 15-16, in Miami.

Transcription:
I’m excited to see new therapeutic strategies being discussed and I think this meeting has come a long way to actually bring different disciplines together. So, you know, we will be seeing the discussion of new targets in terms of new clinical data, but there’s also great talks that I’ve been looking forward to from laboratory investigators telling us about their efforts identifying new targets from a basic science perspective.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.